Brief: Expres2ion Completes GLP Safety Study For ES2B-C001 (HER2-VLP) Breast Cancer Vaccine Candidate
16/04/2024 13:50
April 16 (Reuters) - ExpreS2ion Biotech Holding AB
EXPRS2.ST :
* ANNOUNCES COMPLETION OF GLP SAFETY STUDY FOR ES2B-C001
(HER2-VLP) BREAST CANCER VACCINE CANDIDATE
Source text for Eikon: ID:nWkr5yXR4g
Further company coverage: EXPRS2.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on ExpreS2ion Biotech Holding AB
See all newsBrief: Expres2ion Biotech To Raise SEK 19.3 Million From Warrants And Share Issue
Brief: ExpreS2ion Reports Q2 Loss Of SEK 9.7 Million
Brief: Expres2ion Biotech Says DSMB Recommends Expanding 450 Μg Cohort
Brief: Expres2ion Biotech Holding Q1 2026 Operating Income SEK 6.87 Mln
Brief: Expres2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations